SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending due to rising market anxiety over significant AI disruption impacting software and cybersecurity stocks, coupled with escalating geopolitical tensions from potential new US tariffs and military action in Iran. The community is actively discussing impending NVDA earnings and Bitcoin volatility as key factors influencing the S&P 500's uncertain path.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is trending as solid revenue and subscriber growth from its recent earnings are weighed against community concerns over squeezed margins and ongoing legal and regulatory challenges, particularly regarding its compounded GLP-1 offerings, fueling intense debate between bulls and bears.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending after a sharp stock decline, triggered by an Anthropic blog post touting its AI's ability to automate COBOL modernization, which has ignited community debate over whether this represents a fundamental AI disruption to IBM's legacy services or an overreaction creating a significant buying opportunity.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending due to its global collaboration with Astellas on the VIR-5500 oncology program, which includes $335 million in upfront and near-term payments and up to $1.37 billion in potential milestones. This deal, coupled with positive Phase 1 clinical data, has the community buzzing about significant financial terms and a potential short squeeze, although some caution against a typical post-news pullback.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is experiencing an "AI scare trade" sell-off following a Citrini Research report suggesting AI agents could disrupt its core interchange revenue model, sparking widespread community debate. While some fear a paradigm shift for legacy finance, others are actively buying the dip, dismissing the threat as overblown given Mastercard's own AI integration efforts, strong earnings, and recent share repurchase program.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is highly discussed following its selection for the Missile Defense Agency's SHIELD contract, a significant development for its quantum technology, yet a short report alleging financial irregularities has sparked a polarized debate, with supporters pointing to recent institutional investments and calling for a short squeeze.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending due to significant market fears that AI, specifically new tools like Google's Project Genie, poses an existential threat to its game engine business, despite a recent Q4 earnings beat and ongoing internal AI development. The community is sharply divided, with some anticipating further declines while others believe the sell-off is overblown and see Unity's robust ecosystem and upcoming AI features as a strong counter to the disruption narrative.

Invesco Capital Management LLC - Invesco India ETF

Invesco India ETF

Invesco India ETF (PIN) is gaining attention as India's economy solidifies its position as the world's fourth-largest, fueled by substantial investments from tech giants like Amazon and Microsoft into its AI and cloud infrastructure. Investors are actively debating the implications of this rapid growth for Indian market ETFs.

BlackRock Institutional Trust Company N.A. - iShares India 50 ETF

iShares India 50 ETF

INDY is trending due to India's robust economic growth and strategic positioning, highlighted by strong PMI figures and a recently sealed free trade agreement with the UK. While trade negotiations with the US face complexities regarding tariffs and energy imports, investors widely see India as a long-term growth market and a compelling alternative to China.

WisdomTree Trust - WisdomTree India Earnings Fund

This India-focused ETF is drawing attention as traders evaluate its performance against fluctuating Indian markets and a weakening rupee, while the community continues to debate India's strong long-term growth narrative versus its recent underperformance compared to other emerging markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gyre Therapeutics reported a successful pre–New Drug Application meeting with Chinese regulators for its liver fibrosis treatment, Hydronidone. China’s Center for Drug Evaluation agreed that existing Phase 3 clinical data support a conditional approval filing, with the drug also eligible for priority review pending formal acceptance. 
Gyre plans to submit an NDA in the first half of 2026 for Hydronidone, which targets liver fibrosis associated with chronic hepatitis B, including early cirrhosis. A confirmatory clinical trial will be conducted to support full approval in China. The regulatory update follows positive Phase 3 results announced in May 2025, showing fibrosis regression at Week 52 in 52.85% of treated patients versus 29.84% with placebo. 
Hydronidone previously received Breakthrough Therapy Designation from China’s regulator, highlighting its potential to address a major unmet need where no approved antifibrotic therapies currently exist. 
$GYRE

StockTwits Web

Gyre Therapeutics Inc

Gyre Therapeutics reported a successful pre–New Drug Application meeting with Chinese regulators for its liver fibrosis treatment, Hydronidone. China’s Center for Drug Evaluation agreed that existing Phase 3 clinical data support a conditional approval filing, with the drug also eligible for priority review pending formal acceptance. 
Gyre plans to submit an NDA in the first half of 2026 for Hydronidone, which targets liver fibrosis associated with chronic hepatitis B, including early cirrhosis. A confirmatory clinical trial will be conducted to support full approval in China. The regulatory update follows positive Phase 3 results announced in May 2025, showing fibrosis regression at Week 52 in 52.85% of treated patients versus 29.84% with placebo. 
Hydronidone previously received Breakthrough Therapy Designation from China’s regulator, highlighting its potential to address a major unmet need where no approved antifibrotic therapies currently exist. 
